Fc gamma RIIIA/CD16a Antibody (BLR162J)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14736
Recombinant Monoclonal
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit Clone # BLR162J
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
between 204 and 254 (C-term)
Clonality
Monoclonal
Host
Rabbit
Scientific Data Images for Fc gamma RIIIA/CD16a Antibody (BLR162J)
Immunohistochemistry: Fc gamma RIIIA/CD16a Antibody (BLR162J) [NBP3-14736]
Immunohistochemistry: Fc gamma RIIIA/CD16a Antibody (BLR162J) [NBP3-14736] - Rabbit anti-CD16A recombinant monoclonal antibody. HRP-conjugated goat anti-rabbit IgG.Immunohistochemistry: Fc gamma RIIIA/CD16a Antibody (BLR162J) [NBP3-14736]
Immunohistochemistry: Fc gamma RIIIA/CD16a Antibody (BLR162J) [NBP3-14736] - Rabbit anti-CD16A recombinant monoclonal antibody. HRP-conjugated goat anti-rabbit IgG.Immunohistochemistry: Fc gamma RIIIA/CD16a Antibody (BLR162J) [NBP3-14736]
Immunohistochemistry: Fc gamma RIIIA/CD16a Antibody (BLR162J) [NBP3-14736] - Rabbit anti-CD16A recombinant monoclonal antibody. HRP-conjugated goat anti-rabbit IgGApplications for Fc gamma RIIIA/CD16a Antibody (BLR162J)
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
>95%
Formulation
Borate Buffered Saline (BBS) pH 8.2 with 0.1% BSA and
Preservative
0.09% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 2 - 8 C / 1 year from date of receipt
Background: Fc gamma RIIIA/CD16a
Activating NK cell receptor function has been harnessed for its potential in tumor immunotherapy (5). One immunotherapy strategy is using bi- and tri-specific NK cell engagers (BiKE and TriKE) to target the Fc gamma RIIIA/CD16a receptor with tumor-associated antigens to stimulate a cytotoxic response and mount an attack on tumor cells (5). CD16a is also capable of antibody dependent cellular cytotoxicity (ADCC) through recognition of antibodies bound to target cells (5-6). CD16-induced NK cell activation allows for NK co-receptor expression including stimulatory receptors like CD137 or inhibitory receptors like TIGIT and PD-1, which serve as additional regulatory checkpoints during ADCC (6). Therapeutic antibodies for cancer treatment like rituximab or trastuzumab can be recognized by Fc gamma RIIIA/CD16a to activate NK cell-mediated killing of tumor cells (5-6).
References
1. Fossati, G., Bucknall, R. C., & Edwards, S. W. (2001). Fcgamma receptors in autoimmune diseases. European Journal of Clinical Investigation, 31(9), 821-831. https://doi.org/10.1046/j.1365-2362.2001.00881.x
2. Patel, K. R., Roberts, J. T., & Barb, A. W. (2019). Multiple Variables at the Leukocyte Cell Surface Impact Fc gamma Receptor-Dependent Mechanisms. Frontiers in Immunology, 10, 223. https://doi.org/10.3389/fimmu.2019.00223
3. Moldovan, I., Galon, J., Maridonneau-Parini, I., Roman Roman, S., Mathiot, C., Fridman, W. H., & Sautes-Fridman, C. (1999). Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunology Letters, 68(1), 125-134. https://doi.org/10.1016/s0165-2478(99)00041-3
4. Uniprot (P08637)
5. Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., & Moretta, L. (2021). NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 80, 100870. https://doi.org/10.1016/j.mam.2020.100870
6. Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., Lopez-Diaz de Cerio, A., Cabo, M., Lopez-Botet, M., & Melero, I. (2017). Targeting NK-cell checkpoints for cancer immunotherapy. Current Opinion in Immunology, 45, 73-81. https://doi.org/10.1016/j.coi.2017.01.003
Long Name
Fc gamma Receptor III A
Alternate Names
CD16a, FCGR3A, FcgRIIIA
Gene Symbol
FCGR3A
Additional Fc gamma RIIIA/CD16a Products
Product Documents for Fc gamma RIIIA/CD16a Antibody (BLR162J)
Product Specific Notices for Fc gamma RIIIA/CD16a Antibody (BLR162J)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...